RT Journal Article
SR Electronic
T1 The OMERACT MRI in Arthritis Working Group — Update on Status and Future Research Priorities
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2470
OP 2472
DO 10.3899/jrheum.141248
VO 42
IS 12
A1 Østergaard, Mikkel
A1 Bird, Paul
A1 Gandjbakhch, Frédérique
A1 Eshed, Iris
A1 Haugen, Ida K.
A1 Haavardsholm, Espen A.
A1 Lillegraven, Siri
A1 Foltz, Violaine
A1 Glinatsi, Daniel
A1 Peterfy, Charles
A1 Ejbjerg, Bo
A1 Bøyesen, Pernille
A1 Mease, Philip J.
A1 Hermann, Kay-Geert
A1 Emery, Paul
A1 Genant, Harry K.
A1 Conaghan, Philip G.
YR 2015
UL http://www.jrheum.org/content/42/12/2470.abstract
AB Objective. To provide an update on the status and future research priorities of the Outcome Measures in Rheumatology (OMERACT) magnetic resonance imaging (MRI) in arthritis working group.Methods. A summary is provided of the activities of the group within rheumatoid arthritis (RA), psoriatic arthritis (PsA), and osteoarthritis (OA), and its research priorities.Results. The OMERACT RA MRI score (RAMRIS) evaluating bone erosion, bone edema (osteitis), and synovitis is now the standard method of quantifying articular pathology in RA trials. Cartilage loss is another important part of joint damage, and at the OMERACT 12 conference, we provided longitudinal data demonstrating reliability and sensitivity to change of the RAMRIS JSN component score, supporting its use in future clinical trials. The MRI group has previously developed a PsA MRI score (PsAMRIS). At OMERACT 12, PsAMRIS was evaluated in a randomized placebo-controlled trial of patients with PsA, demonstrating the responsiveness and discriminatory ability of applying the PsAMRIS to hands and feet. A hand OA MRI score (HOAMRIS) was introduced at OMERACT 11, and has subsequently been further validated. At OMERACT 12, good cross-sectional interreader reliability, but variable reliability of change scores, were reported. Potential future research areas were identified at the MRI session at OMERACT 12 including assessment of tenosynovitis in RA and enthesitis in PsA and focusing on alternative MRI techniques.Conclusion. MRI has been further developed and validated as an outcome measure in RA, PsA, and OA. The group will continue its efforts to optimize the value of MRI as a robust biomarker in rheumatology clinical trials.